- This Week in Managed Care: November 9, 2018 (ajmc.com)
Samantha DiGrande, Welcome to This Week in Managed Care from the Managed Markets News Network
- Flushed Pharmaceuticals Are Likely Drugging Stream Dwellers Like The Platypus (blogs.discovermagazine.com)A diverse suite of pharmaceuticals contaminates stream and riparian food webs (nature.com)
The pharmaceuticals that our bodies don’t use are cleared from our systems and flushed down into sewage systems, processed in water treatment plants, and finally dumped into streams and other waterways...an alarming number of pharmaceutical compounds aren’t filtered out during the treatment process. Research...shows that this might have an even bigger effect on stream ecosystems than anyone expected...A range of drugs used by humans were detected in Australian stream invertebrates and the spiders that eat them. The researchers have reason to worry that this will have compounding effects up the food chain – to stream predators like trout, or Australian favorite the platypus.
- This Week in Managed Care: October 26, 2018 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network...
- This Week in Managed Care: October 19, 2018 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- November 9 Pharmacy Week in Review: Study Findings Support CDC Recommendations for Annual Flu Vaccine Among Children (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- This Week in Managed Care: November 2, 2018 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- October 26 Pharmacy Week in Review: FDA Addressing Accessibility of Naloxone, Therapy Shows Potential for Treating Pancreatic Cancer (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- FDA unveils open source code for collecting patient data (healthcareitnews.com)FDA’s MyStudies Application (App) (fda.gov)
The Food and Drug Administration launched a new app Wednesday to gather data for clinical trials and other research directly from patients...The FDA released the MyStudies app source code to the public, allowing developers and researchers to tailor the app to suit their research needs. The agency designed the app to facilitate the use of real-world data in research...Patients can submit real-world data to the app via their mobile devices. Researchers can then link those data to other electronic health information. The goal is to improve drug development...“Better capture of real world data, collected from a variety of sources, has the potential to make our new drug development process more efficient, improve safety and help lower the cost of product development,” FDA Commissioner Dr. Scott Gottlieb said in a statement. “Our hope is that the collection of more real world data directly from patients, using a secure app, will lead to more efficient product development and assist with safety monitoring.”
- November 2 Pharmacy Week in Review: Narcolepsy Treatment Approved for Pediatric Patients, Study Finds Possible Link Between Thyroid Disease and RA (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- Advancing Toward the Goal of Global Approval for Generic Drugs: FDA Proposes Critical First Steps to Harmonize the Global Scientific and Technical Standards for Generic Drugs (fda.gov)
Scott Gottlieb, M.D., Commissioner of Food and Drugs
...FDA launched a Drug Competition Action Plan that focuses on three key areas designed to facilitate more generic competition, promote patient access, and improve the economics of developing generic medicines...While we’ve made substantial progress in fostering more competition by resolving obstacles that can make it difficult to win approval of generic versions of certain complex drugs, increasing the speed of generic approvals, and closing down ways that branded companies game the system to prolong drug monopolies, there’s still more work to be done...So we’re opening up some new policy fronts when it comes to our Drug Competition Action Plan. And we’re re-launching that plan for 2019 with some additional initiatives. Chief among them is a new effort that FDA has proposed to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), a key international body comprised of other regulatory authorities and the pharmaceutical industry: The pursuit of common global development standards for generic drugs...The ultimate goal of this global harmonization of scientific and technical requirements would be the attainment of a single global generic drug development program that can support simultaneous regulatory filings across multiple markets. Harmonization of these requirements is foundational to achieving a future goal of enabling global approval for high quality generic drugs.